666235-33-2

Basic information

• Product Name: 1H-Pyrazole-4-carboxamide,5-amino-1-cyclopentyl-(9CI)
• Synonyms: 1H-Pyrazole-4-carboxamide,5-amino-1-cyclopentyl-(9CI);5-amino-1-cyclopentyl-1H-pyrazole-4-carboxamide;1H-Pyrazole-4-carboxamide, 5-amino-1-cyclopentyl-
• CAS NO: 666235-33-2
• Molecular Formula: C₉H₁₄N₄O
• Molecular Weight: 194.23366
• Product Categories: CYCLOPENTANE
• Mol File: 666235-33-2.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 416.211°C at 760 mmHg
• Flash Point: 205.517°C
• Appearance: /
• Density: 1.532g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.73
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 1H-Pyrazole-4-carboxamide,5-amino-1-cyclopentyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-4-carboxamide,5-amino-1-cyclopentyl-(9CI)(666235-33-2)
• EPA Substance Registry System: 1H-Pyrazole-4-carboxamide,5-amino-1-cyclopentyl-(9CI)(666235-33-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 666235-33-2(Hazardous Substances Data)

Usage

General Description

1H-Pyrazole-4-carboxamide, 5-amino-1-cyclopentyl-(9CI) is a chemical compound that belongs to the class of pyrazole derivatives. It is characterized by a pyrazole ring containing an amide and amino group, as well as a cyclopentyl substituent. 1H-Pyrazole-4-carboxamide,5-amino-1-cyclopentyl-(9CI) has potential pharmaceutical and biological activities, and its structural features make it suitable for use in the development of drugs targeting specific biological mechanisms. It may act as a ligand for certain receptors or enzymes, and its unique structure may confer specific properties that can be used for therapeutic purposes. The synthesis and study of this compound's biological activity could lead to the development of new drugs with improved efficacy or reduced side effects.

InChI:InChI=1/C9H14N4O/c10-8-7(9(11)14)5-12-13(8)6-3-1-2-4-6/h5-6H,1-4,10H2,(H2,11,14)

Upstream product

• 30929-67-0 5-amino-1-cyclopentyl-1H-pyrazole-4-carbonitrile 

Downstream Products

• 1236858-90-4 1-cyclopentyl-6-[(1S)-1-(3-phenoxyazetidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1236858-92-6 1-cyclopentyl-6-[(1R)-1-(3-phenoxyazetidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1402155-51-4 C₂₄H₃₁N₅O 
• 1236859-40-7 1-cyclopentyl-6-[1-(3-phenylpyrrolidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1548588-80-2 6-[(4-chlorophenyl)thio]methyl-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
• 1548588-39-1 1-cyclopentyl-6-(phenoxymethyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 

Relevant articles and documents

Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles

Here, we present a series of dual-target phosphodiesterase 9 (PDE9) and histone deacetylase (HDAC) inhibitors devised as pharmacological tool compounds for assessing the implications of these two targets in Alzheimer's disease (AD). These novel inhibitors were designed taking into account the key pharmacophoric features of known selective PDE9 inhibitors as well as privileged chemical structures, bearing zinc binding groups (hydroxamic acids and ortho-amino anilides) that hit HDAC targets. These substituents were selected according to rational criteria and previous knowledge from our group to explore diverse HDAC selectivity profiles (pan-HDAC, HDAC6 selective, and class I selective) that were confirmed in biochemical screens. Their functional response in inducing acetylation of histone and tubulin and phosphorylation of cAMP response element binding (CREB) was measured as a requisite for further progression into complete in vitro absorption, distribution, metabolism and excretion (ADME) and in vivo brain penetration profiling. Compound 31b, a selective HDAC6 inhibitor with acceptable brain permeability, was chosen for assessing in vivo efficacy of these first-in-class inhibitors, as well as studying their mode of action (MoA).

Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer’s disease

Phosphodiesterase-9 (PDE9) is a promising target for treatment of Alzheimer’s disease (AD). To discover multifunctional anti-AD agents with capability of PDE9 inhibition and antioxidant activity, a series of novel pyrazolopyrimidinone derivatives, couplin

Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease

Discovery of multitarget-directed ligands (MTDLs), targeting different factors simultaneously to control the complicated pathogenesis of Alzheimer's disease (AD), has become an important research area in recent years. Both phosphodiesterase 9A (PDE9A) and butyrylcholinesterase (BuChE) inhibitors could participate in different processes of AD to attenuate neuronal injuries and improve cognitive impairments. However, research on MTDLs combining the inhibition of PDE9A and BuChE simultaneously has not been reported yet. In this study, a series of novel pyrazolopyrimidinone-rivastigmine hybrids were designed, synthesized, and evaluated in vitro. Most compounds exhibited remarkable inhibitory activities against both PDE9A and BuChE. Compounds 6c and 6f showed the best IC50 values against PDE9A (6c, 14 nM; 6f, 17 nM) together with the considerable inhibition against BuChE (IC50, 6c, 3.3 μM; 6f, 0.97 μM). Their inhibitory potencies against BuChE were even higher than the anti-AD drug rivastigmine. It is worthy mentioning that both showed moderate selectivity for BuChE over acetylcholinesterase (AChE). Molecular docking studies revealed their binding patterns and explained the influence of configuration and substitutions on the inhibition of PDE9A and BuChE. Furthermore, compounds 6c and 6f exhibited negligible toxicity, which made them suitable for the further study of AD in vivo.